{
  "id": 20893817,
  "title": "H.C. Wainwright reiterates Buy on Teva Pharma stock, $54 target",
  "url": "https://urgent.news/2026/11/20/h-c-wainwright-reiterates-buy-on-teva-pharma-stock-54-target",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T12:00:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-on-teva-pharma-stock-54-target-93CH-5041467"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has reaffirmed its Buy rating on Teva Pharmaceutical Industries (NYSE:TEVA) and maintained a $54.00 price target. The firm noted that Teva's management has expressed confidence in the continuity of research and development efforts following Eric Hughes' departure as Chief Medical Officer and Executive Vice President of Global R&D. David Gardiner, Head of Innovative Medicines & Clinical Development, is now leading the R&D transition, reporting directly to CEO Richard Francis. Hughes is expected to oversee the handover until year-end, with external R&D communications transferring to Gardiner. Teva CEO Francis expressed confidence that Hughes' departure would not affect the execution of existing programs, including duvakitug and IL-15, which are managed by dedicated program and regulatory leads. Teva reported third-quarter revenue of $4.395 billion, a 2% year-over-year decline but a 6% sequential increase. Non-GAAP earnings per share were $0.86, beating consensus estimates of $0.72. Teva also settled a patent infringement lawsuit with Alkermes and announced positive responses to its recent R&D Day from other analyst firms. H.C. Wainwright raised its price target to $54, highlighting Teva's shift towards an innovation-led biopharmaceutical company.",
  "summary": null,
  "key_points": [
    "H.C. Wainwright reaffirms Buy rating on Teva Pharma with $54 target",
    "Eric Hughes departs as CMO, David Gardiner leads R&D transition",
    "Teva reports Q3 revenue of $4.395B, 6% sequential EPS growth"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}